Vaxart, Inc.
Close on Oct 19, 2026
- Market cap
- $115.15M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $27.20M | $-0.06 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | $39.20M | $0.02 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | $72.40M | $-0.04 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | During market hours | $39.70M | $-0.07 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | $20.90M | $-0.07 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 21, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | $4.90M | $-0.06 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | During market hours | – | – | – |
Press releases
Announcements Vaxart filed with the SEC
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vaxart Announces Results of Annual Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
VAXART, INC. PRESS RELEASE DATED JULY 1, 2026
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Material agreement · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MAY 19, 2026
Other events · EX-99.1 to Form 8-K
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart Provides Business Update and Reports Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Dynavax Enters Exclusive License Agreement for Vaxart ’ s Novel Oral COVID-19 Vaccine Program
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart Announces Adjournment of Special Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart Granted Extension by Nasdaq to Regain Compliance
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
David Carey - Finn Partners
Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart to Host Virtual Stockholder Fireside Chat on Wednesday, August 20 to Discuss Reverse Stock Split Proposal
Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vaxart Announces Trading on OTCQX Best Market
Other events · EX-99.1 to Form 8-K
Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart Announces Adjournment of Annual Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart Answers Additional Frequently Asked Questions from Retail Investors
Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
Other events · EX-99.1 to Form 8-K
Vaxart Announces Adjournment of Annual Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting
Other events · EX-99.1 to Form 8-K
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
Other events · EX-99.1 to Form 8-K
Vaxart Appoints Jeroen Grasman as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement
Other events · EX-99.1 to Form 8-K
Despite extreme volatility from macroeconomic disruption resulting in substantial challenges within the biotech sector, Vaxart has done a remarkable job navigating this environment and believes it remains well-positioned to transform global public health with oral pill vaccines.
Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress
Regulation FD disclosure · EX-99.2 to Form 8-K
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
Other events · EX-99.1 to Form 8-K
Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
Other events · EX-99.1 to Form 8-K
Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs
Other events · EX-99.2 to Form 8-K
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Other events · EX-99.1 to Form 8-K
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Material agreement · Other events · EX-99.1 to Form 8-K